In our clinical trial, we investigated the effects of methylsulfonylmethane (MSM) combined with boswellic acids (BA) on individuals suffering from knee arthritis, a chronic condition often characterized by joint pain and inflammation. We enrolled 60 participants who were randomly divided into two groups: one group received the MSM and BA treatment for 60 days, and the other group was given a placebo.
Over the follow-up periods of 2 and 6 months, we measured pain levels using a visual analog scale (VAS) and assessed joint function with the Lequesne index (LI). While we found that participants taking MSM and BA reported higher pain levels than those on the placebo after 2 months, these differences did not persist at the 6-month mark. Furthermore, when evaluating joint function, we noted no significant differences between the two groups.
However, one notable finding was that those receiving the combination treatment needed fewer anti-inflammatory drugs compared to the placebo group at both follow-up points. Despite the reduced reliance on these medications, we concluded that combined treatment with MSM and BA did not significantly improve pain or joint function compared to placebo.
Read More